Results 51 to 60 of about 7,662 (208)
Neck‐vein thrombosis during spaceflight
British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 24-34, January 2026.Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley +1 more source
Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis +3 more
wiley +1 more source
Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of Infective Endocarditis in Humans? [PDF]
, 2017 Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot be prevented by circumstantial antibiotic prophylaxis.
Chaouch, Aziz +7 more
core
Thrombosis Journal, 2012 Background There has been a shift towards greater use of neuraxial over general anaesthesia for patients undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce adverse effects have recently been put ...
Rosencher Nadia +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1499-1511, December 2025.Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (Fa), intestinal availability (Fg), CYP3A4 induction, and
Paresh P. Chothe +4 more
wiley +1 more source
Case Reports in Medicine, 2013 Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim +6 more
doaj +1 more source
Antikoagulandid virvendusarütmia tüsistuste ennetamisel Eestis –kulutõhusus ja maksumus [PDF]
, 2016 Taust ja eesmärk. Hinnata virvendusarütmia tüsistuste ennetamiseks kasutatavate uute suukaudsete antikoagulantide – dabigatraani ja rivaroksabaani – kulutõhusust ja eelarvemõju võrrelduna standardse varfariinraviga.
Aleksandrova, Julia +9 more
core +2 more sources
Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation
, 2013 The most significant complication of atrial fibrillation (AF) is thromboembolic stroke. Furthermore, the consequences of AF-related stroke tend to be more severe than those of other aetiologies.
Connelly, D.T., Lang, N.N.
core +1 more source
Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use [PDF]
, 2012 OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough, fatigue, and bloody stools.
Dy, Eliza A., Shiltz, Dane L.
core +2 more sources
Catheterization and Cardiovascular Interventions, Volume 106, Issue 3, Page 2037-2047, September 1, 2025.ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki +13 more
wiley +1 more source